Trials have shown that the vaccine, mFlusiva, is 27 percent more effective at preventing flu than standard-dose vaccines for people in this age group. Select pharmacies and other immunization sites ...
WASHINGTON, DC – The U.S. Food and Drug Administration (FDA) has approved the country’s first mRNA-based influenza vaccine, developed by Moderna. The vaccine is approved for adults aged 50 to 64 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results